Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?


Drug Profile


Alternative Names: AQ4N; AZD 1689

Latest Information Update: 02 Feb 2011

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator University of London School of Pharmacy
  • Developer Novacea; Transcept Pharmaceuticals Inc
  • Class Anthraquinones; Antineoplastics; Small molecules
  • Mechanism of Action DNA intercalators; Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued B-cell lymphoma; Glioblastoma; Precursor cell lymphoblastic leukaemia-lymphoma

Most Recent Events

  • 02 Feb 2009 Novacea has merged with Transcept Pharmaceuticals to form Transcept Pharmaceuticals Inc
  • 15 Feb 2008 Pharmacokinetics data from a phase I proof-of-principle trial in solid tumours released by Novacea
  • 03 Jan 2008 Novacea has scaled back development of banoxantrone, discontinuing the phase II trial in acute lymphoblastic leukaemia and delaying the planned clinical trial in B cell lymphoma
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top